Rudolf Fuchshofer
Overview
Explore the profile of Rudolf Fuchshofer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
2055
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sonntag T, Froemel F, Stamer W, Ohlmann A, Fuchshofer R, Breunig M
Pharmaceutics
. 2021 Jul;
13(6).
PMID: 34204364
In glaucoma therapy, nanoparticles (NPs) are a favorable tool for delivering drugs to the outflow tissues of the anterior chamber of the eye where disease development and progression take place....
12.
Weiss M, Reinehr S, Mueller-Buehl A, Doerner J, Fuchshofer R, Stute G, et al.
Int J Mol Sci
. 2021 Mar;
22(4).
PMID: 33671472
To reveal the pathomechanisms of glaucoma, a common cause of blindness, suitable animal models are needed. As previously shown, retinal ganglion cell and optic nerve degeneration occur in βB1-CTGF mice....
13.
Schneider M, Pawlak R, Weber G, Dillinger A, Kuespert S, Iozzo R, et al.
Matrix Biol
. 2021 Feb;
97:1-19.
PMID: 33582236
Primary open-angle glaucoma, a neurodegenerative disorder characterized by degeneration of optic nerve axons, is a frequent cause of vision loss and blindness worldwide. Several randomized multicenter studies have identified intraocular...
14.
Dillinger A, Kuespert S, Froemel F, Tamm E, Fuchshofer R
Cell Tissue Res
. 2021 Jan;
384(3):625-641.
PMID: 33512643
CCN2/CTGF is a matricellular protein that is known to enhance transforming growth factor-β signaling and to induce a myofibroblast-like phenotype in a variety of cell types. Here, we investigated Ccn2/Ctgf...
15.
Mietzner R, Kade C, Froemel F, Pauly D, Stamer W, Ohlmann A, et al.
Pharmaceutics
. 2020 Jul;
12(8).
PMID: 32727014
Rho-associated protein kinase (ROCK) inhibitors allow for causative glaucoma therapy. Unfortunately, topically applied ROCK inhibitors suffer from high incidence of hyperemia and low intraocular bioavailability. Therefore, we propose the use...
16.
Boesl F, Drexler K, Muller B, Seitz R, Weber G, Priglinger S, et al.
Mol Vis
. 2020 Mar;
26:135-149.
PMID: 32180679
Purpose: To analyze whether activation of endogenous wingless (Wnt)/β-catenin signaling in Müller cells is involved in protection of retinal ganglion cells (RGCs) following excitotoxic damage. Methods: Transgenic mice with a...
17.
Kassumeh S, von Studnitz A, Priglinger S, Fuchshofer R, Luft N, Moloney G, et al.
Acta Ophthalmol
. 2020 Feb;
98(6):e773-e780.
PMID: 32017400
Purpose: To determine whether excimer laser ablation of guttae is a viable strategy for removal of diseased tissue in Fuchs' endothelial corneal dystrophy (FECD) on excised human Descemet membranes and...
18.
Kassumeh S, Leopold S, Fuchshofer R, Thomas C, Priglinger S, Tamm E, et al.
Cells
. 2020 Jan;
9(2).
PMID: 31979254
Purpose: To investigate whether and how leukemia inhibitory factor (Lif) is involved in mediating the neuroprotective effects of Norrin on retinal ganglion cells (RGC) following excitotoxic damage. Norrin is a...
19.
Reinehr S, Koch D, Weiss M, Froemel F, Voss C, Dick H, et al.
J Cell Mol Med
. 2019 May;
23(8):5497-5507.
PMID: 31144440
Primary open-angle glaucoma (POAG) is one of the most common causes for blindness worldwide. Although an elevated intraocular pressure (IOP) is the main risk factor, the exact pathology remained indistinguishable....
20.
Dillinger A, Guter M, Froemel F, Weber G, Perkumas K, Stamer W, et al.
Small
. 2018 Oct;
14(50):e1803239.
PMID: 30353713
Glaucoma is the second leading cause of blindness worldwide, often associated with elevated intraocular pressure. Connective tissue growth factor (CTGF) is a mediator of pathological effects in the trabecular meshwork...